PTPRC and neoplasm: The percentage of Th2 cells (CD3+CD45+CCR6−CXCR3−CCR10−) was higher in the TM (#P < 0.05 vs. TC) and combinatorial therapy groups (∗P < 0.05 vs. T and ##P < 0.01 vs. TC) than that in the cisplatin-treated and/or untreated tumor-bearing mice.